MSD’s KEYTRUDA® significantly improves survival compared to chemotherapy in NSCLC
KEYNOTE-010 published in the Lancet and to be presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick European Conferences and Symposia Practical therapeutics Oncology chemotherapy esmo KEYNOTE-010 keytruda Latest News non-small cell lung cancer pembrolizumab Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Conferences | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Politics